CEOs AGM Presentation
Filed with ASX · · 9 pages · English
The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify the
Earlier from CSL
- New Debt Facilities
- FDA Approves Privigen for CIDP Indication
- CSL Behring Acquires US Biotech Company Calimmune
- 2017 FY Results Announcement and Analysts Presentation
- Appendix 4E, Directors Report and Financial Statements
Later from CSL
- CSL Lifts Profit Guidance
- Full Year Statutory Accounts
- Full Year Results Announcement
- CSL R&D Investor Briefing
- Appendix 4D and Half Year Accounts
Follow CSL into a list and get an email when it puts out news.
Follow CSL